Your gift is 100% tax deductible.
Chemotherapy for Nasopharyngeal Cancer
Chemotherapy (chemo) is the use of anti-cancer drugs to treat cancer. It can be given as treatment for nasopharyngeal cancers, either by itself or along with radiation therapy (known as chemoradiation).
Nasopharyngeal cancer is not common in the US, and these cancers are located near many critical structures in your head and neck. It’s very important to go to a cancer center with experience treating NPC.
How is chemotherapy used to treat nasopharyngeal cancers?
Chemo can be used in several different ways to treat nasopharyngeal cancer (NPC):
- Chemoradiation is chemo given along with radiation therapy. This is the main treatment for more advanced stages of NPC.
- Induction chemotherapy is given as the first treatment before chemoradiation. This method can help some people with NPC live longer.
- Adjuvant chemotherapy is given after radiation or chemoradiation.
Chemo can also be given alone or in combination with either targeted therapy or immunotherapy to treat NPC that cannot be surgically removed (unresectable), has spread to beyond the head and neck area (metastatic), or has come back after initial treatment (recurrent).
How is chemo given?
Chemo drugs are most often given into a vein (IV) or by mouth, which allows them to enter the bloodstream and reach most parts of the body. This can be done in a doctor’s office, infusion center, or hospital setting.
Chemo is often given using a slightly larger and sturdier IV known as a central venous catheter (CVC), central venous access device (CVAD), or central line. There are many types of CVCs. The most common are the port and the PICC line. These are used to put medicines, blood products, nutrients, or fluids directly into your blood. They can also be used to take blood for tests.
Chemotherapy is given in cycles: one drug or a combination of drugs given on a set schedule, followed by a rest period. This period of chemo and rest is considered one cycle. The chemo schedule repeats to start the next cycle.
The exact schedule depends on the drugs used, but a common chemo cycle could be once a week, once every 3 weeks, or once every 4 weeks.
Common chemo drugs used to treat NPC
Cisplatin is the chemo drug used most often to treat NPC. It can be used alone or as part of chemoradiation (see below). It may be combined with another chemo drug to be given after chemoradiation or as induction chemotherapy.
Carboplatin is sometimes used if cisplatin is not a good choice.
Other drugs might also be helpful in treating NPC with or without radiation, including:
- Gemcitabine (Gemzar)
- Docetaxel (Taxotere)
- Fluorouracil, 5-FU (Adrucil)
- Capecitabine (Xeloda)
- Paclitaxel (Taxol)
A chemo drug may be used alone or combined with other drugs. Combining drugs often shrinks tumors better but tends to cause more side effects.
Chemoradiation for NPC
Chemoradiation is chemotherapy given at the same time as radiation.
It has been shown to shrink nasopharyngeal tumors more than either treatment alone. This combined approach is helpful for people whose cancers are locally advanced, but it can be hard to tolerate, especially for people in poor health.
A preferred schedule is a dose of the chemo drug cisplatin every 3 weeks during radiation. For people who can’t tolerate cisplatin, carboplatin might be used with radiation instead.
Possible side effects of chemotherapy
Chemo drugs attack cells that divide quickly, which is why they work against cancer cells. But other cells in the body also divide quickly, including cells in the bone marrow, the lining of the mouth and intestines, and the hair follicles. This can lead to certain side effects.
These side effects vary depending on the type of chemo drugs, the dose, and the length of time they are given.
Common side effects
Common short-term side effects of chemo can include:
- Hair loss
- Mouth sores
- Loss of appetite
- Nausea and vomiting
- Diarrhea
- Fever
- Rash
Chemo can also affect the blood-producing cells of the bone marrow, which can lead to:
- Increased chance of infections, from low white blood cell counts
- Easy bruising or bleeding, from low platelet counts
- Fatigue, from low red blood cell counts
Side effects of specific chemo drugs
Along with the risks above, some side effects are seen more often with certain chemo drugs. For example:
- 5-FU often causes diarrhea. This might need treatment with drugs like loperamide.
- Cisplatin, docetaxel, and paclitaxel can cause nerve damage (neuropathy), leading to hearing loss or numbness and tingling in the hands and feet. This often improves once treatment stops, but for some people it lasts a long time.
- Cisplatin can also damage the kidneys. To help prevent this, intravenous (IV) fluid is given before and after each dose.
Managing side effects
Chemo side effects usually go away over time after treatment ends. There are also ways to prevent or treat many of these side effects. Tell your cancer care team if you have side effects from chemo, so they can help you manage them. For example, many drugs are available to help prevent or treat nausea and vomiting.
In some cases, the doses of chemo drugs may be reduced or treatment may need to be delayed or stopped to keep side effects from getting worse.
More information about chemotherapy
For more general information about how chemotherapy is used to treat cancer, see Chemotherapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
- Written by
- References
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
Bae WK, Hwang JE, Shim HJ, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol 2010;65:589-595.
Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-539.
Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res 2018;24:1824-1833.
Dechaphunkul T, Pruegsanusak K, Sangthawan D, Sunpaweravong P. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. Head Neck Oncol 2011;3:30.
Leeman JE, Katabi N, Wong RJ, Lee NY and Romesser PB. Ch. 65 - Cancer of the Head and Neck. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier; 2020.
Liu GY, Li WZ, Wang DS, et al. Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: A phase 3 randomized clinical trial. JAMA Oncol 2022;8:553-561.
Mendenhall WM, Dziegielewski PT, and Pfister DG. Chapter 45- Cancer of the Head and Neck. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 12th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2023.
National Cancer Institute. Nasopharyngeal Cancer Treatment (Adult) (PDQ)–Health Professional Version. May 14, 2025. Accessed at www.cancer.gov/types/head-and-neck/hp/adult/nasopharyngeal-treatment-pdq on January 28, 2026.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers, Version 1.2026. Accessed at www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf on Jan 28, 2026.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Smoking Cessation. V.2.2025 – December 3, 2025. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/smoking.pdf on Januargy 28, 2026.
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.
Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomized controlled trial. Lancet Oncol 2016;17:1509-1520.
Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019;381:1124-1135.
Last Revised: March 3, 2026
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.


